By European Pharmaceutical Review on July 13, 2023

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. Yet the pace of adoption in Europe has notably lagged countries such as Canada, Australia and the US. In many countries, medical cannabis is only utilised as a therapy when licensed medications have proven ineffective. Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. Europe, however, is well placed to become a leader in driving the clinical translation of medications that display significant promise in laboratory-based studies.

– Read the entire article at European Pharmaceutical Review.